

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Peter Droge *et al.*

Serial No.: 10/082,772

Filed: February 25, 2002

For: SEQUENCE-SPECIFIC DNA  
RECOMBINATION IN EUKARYOTIC  
CELLS

Group Art Unit: 1633

Examiner: Nguyen, Quang

Atty. Dkt. No.: DEBE:008US

Confirmation No.: 4391

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

March 13, 2007

Date

  
Steven L. Highlander

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/DEBE:008US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 13, 2007

Form PTO-1449 (modified)		Atty. Docket No.: <b>DEBE:008US</b>	Serial No.: <b>10/082,772</b>
List of Patents and Publications for Applicant's		Applicant: <b>Peter Droge <i>et al.</i></b>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: <b>February 25, 2002</b>	Group: <b>1633</b>
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Darquet <i>et al.</i> , "A new DNA vehicle for nonviral gene delivery: supercoiled minicircle," <i>Gene Therapy</i> , 4:1341-1349, 1997 (Medline Abstract, Abstract Number 1998133161).
	C10	Darquet <i>et al.</i> , "Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer," <i>Gene Therapy</i> , 6:209-218, 1999 (Medline Abstract, Abstract Number 1999363963).
	C11	Hsu <i>et al.</i> , "The lambda phage at site: functional limits and interaction with Int protein," <i>Nature</i> , 285:85-91, 1980 (PubMed Abstract, Abstract Number 6246439).

25754984.1

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	